Clinical trial
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or…
NCT00207103 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00207103 |
|---|---|
| Title | MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors |
| Official title | Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Brivanib, Brivanab |
| Enrollment | 68 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 4, 2008 |
| Countries | Canada, Italy, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: